Literature DB >> 27127187

Overcoming Barriers in Kidney Health-Forging a Platform for Innovation.

Peter G Linde1, Patrick Archdeacon2, Matthew D Breyer3, Tod Ibrahim4, Jula K Inrig5, Reshma Kewalramani6, Celeste Castillo Lee7, Carolyn Y Neuland8, Prabir Roy-Chaudhury9, James A Sloand10, Rachel Meyer4, Kimberly A Smith11, Jennifer Snook12, Melissa West4, Ronald J Falk13.   

Abstract

Innovation in kidney diseases is not commensurate with the effect of these diseases on human health and mortality or innovation in other key therapeutic areas. A primary cause of the dearth in innovation is that kidney diseases disproportionately affect a demographic that is largely disenfranchised, lacking sufficient advocacy, public attention, and funding. A secondary and likely consequent cause is that the existing infrastructure supporting nephrology research pales in comparison with those for other internal medicine specialties, especially cardiology and oncology. Citing such inequities, however, is not enough. Changing the status quo will require a coordinated effort to identify and redress the existing deficits. Specifically, these deficits relate to the need to further develop and improve the following: understanding of the disease mechanisms and pathophysiology, patient engagement and activism, clinical trial infrastructure, and investigational clinical trial designs as well as coordinated efforts among critical stakeholders. This paper identifies potential solutions to these barriers, some of which are already underway through the Kidney Health Initiative. The Kidney Health Initiative is unique and will serve as a current and future platform from which to overcome these barriers to innovation in nephrology.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  Pathophysiology of Renal Disease and Progression; Patient satisfaction; clinical trial; end stage kidney disease; kidney disease

Mesh:

Year:  2016        PMID: 27127187      PMCID: PMC4926987          DOI: 10.1681/ASN.2015090976

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  15 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Race differences in access to health care and disparities in incident chronic kidney disease in the US.

Authors:  Kira Evans; Josef Coresh; Lori D Bash; Tiffany Gary-Webb; Anna Köttgen; Kathryn Carson; L Ebony Boulware
Journal:  Nephrol Dial Transplant       Date:  2010-08-05       Impact factor: 5.992

3.  The paradoxical problem with multiple-IRB review.

Authors:  Jerry Menikoff
Journal:  N Engl J Med       Date:  2010-10-13       Impact factor: 91.245

4.  I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Authors:  A D Barker; C C Sigman; G J Kelloff; N M Hylton; D A Berry; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2009-05-13       Impact factor: 6.875

5.  Trial quality in nephrology: how are we measuring up?

Authors:  Suetonia C Palmer; Michela Sciancalepore; Giovanni F M Strippoli
Journal:  Am J Kidney Dis       Date:  2011-09       Impact factor: 8.860

6.  FDA's Critical Path Initiative.

Authors:  Janet Woodcock
Journal:  Drug Discov Today Technol       Date:  2007

7.  Racial and ethnic differences in mortality among individuals with chronic kidney disease: results from the Kidney Early Evaluation Program (KEEP).

Authors:  Stacey E Jolly; Nilka Ríos Burrows; Shu-Cheng Chen; Suying Li; Claudine T Jurkovitz; Keith C Norris; Michael G Shlipak
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

8.  Loss to analysis in randomized controlled trials in CKD.

Authors:  Aneet Deo; Christopher H Schmid; Amy Earley; Joseph Lau; Katrin Uhlig
Journal:  Am J Kidney Dis       Date:  2011-07-20       Impact factor: 8.860

9.  The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods.

Authors:  Harold I Feldman; Lawrence J Appel; Glenn M Chertow; Denise Cifelli; Borut Cizman; John Daugirdas; Jeffrey C Fink; Eunice D Franklin-Becker; Alan S Go; L Lee Hamm; Jiang He; Tom Hostetter; Chi-Yuan Hsu; Kenneth Jamerson; Marshall Joffe; John W Kusek; J Richard Landis; James P Lash; Edgar R Miller; Emile R Mohler; Paul Muntner; Akinlolu O Ojo; Mahboob Rahman; Raymond R Townsend; Jackson T Wright
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  Association between lack of health insurance and risk of death and ESRD: results from the Kidney Early Evaluation Program (KEEP).

Authors:  Claudine T Jurkovitz; Suying Li; Keith C Norris; Georges Saab; Andrew S Bomback; Adam T Whaley-Connell; Peter A McCullough
Journal:  Am J Kidney Dis       Date:  2013-04       Impact factor: 8.860

View more
  17 in total

Review 1.  Perspectives from the Kidney Health Initiative on Advancing Technologies to Facilitate Remote Monitoring of Patient Self-Care in RRT.

Authors:  Mitchell H Rosner; Susie Q Lew; Paul Conway; Jennifer Ehrlich; Robert Jarrin; Uptal D Patel; Karen Rheuban; R Brooks Robey; Neal Sikka; Eric Wallace; Patrick Brophy; James Sloand
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-14       Impact factor: 8.237

Review 2.  Cellular plasticity in kidney injury and repair.

Authors:  Monica Chang-Panesso; Benjamin D Humphreys
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

3.  A Technology Roadmap for Innovative Approaches to Kidney Replacement Therapies: A Catalyst for Change.

Authors:  Joseph V Bonventre; Frank P Hurst; Melissa West; Iwen Wu; Prabir Roy-Chaudhury; Murray Sheldon
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-27       Impact factor: 8.237

Review 4.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

5.  Clinical Trial End Points for Hemodialysis Vascular Access: Background, Rationale, and Definitions.

Authors:  Surendra Shenoy; Michael Allon; Gerald Beathard; Deborah Brouwer-Maier; Laura M Dember; Mark Glickman; Celeste Lee; Terry Litchfield; Charmaine Lok; Thomas Huber; Prabir Roy-Chaudhury; Jack Work; Melissa West; Haimanot Wasse
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-27       Impact factor: 8.237

Review 6.  Translating Knowledge Into Therapy for Acute Kidney Injury.

Authors:  Mark de Caestecker; Raymond Harris
Journal:  Semin Nephrol       Date:  2018-01       Impact factor: 5.299

Review 7.  Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives.

Authors:  Murilo Guedes; Bruce M Robinson; Gregorio Obrador; Allison Tong; Ronald L Pisoni; Roberto Pecoits-Filho
Journal:  Kidney360       Date:  2020-07-01

Review 8.  Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.

Authors:  Gerald A Beathard; Charmaine E Lok; Marc H Glickman; Ahmed A Al-Jaishi; Donna Bednarski; David L Cull; Jeffery H Lawson; Timmy C Lee; Vandana D Niyyar; Donna Syracuse; Scott O Trerotola; Prabir Roy-Chaudhury; Surendra Shenoy; Margo Underwood; Haimanot Wasse; Karen Woo; Theodore H Yuo; Thomas S Huber
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-20       Impact factor: 8.237

Review 9.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

Review 10.  Kidney disease trials for the 21st century: innovations in design and conduct.

Authors:  William G Herrington; Natalie Staplin; Richard Haynes
Journal:  Nat Rev Nephrol       Date:  2019-10-31       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.